School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Avenida do Café, s/n, Ribeirão Preto, SP, 14040-903, Brazil.
Pharmaceutical Sciences Department, State University of Ponta Grossa, 4748 Carlos Cavalcanti Avenue, Ponta Grossa, PR, 84030-900, Brazil.
Drug Deliv Transl Res. 2020 Dec;10(6):1810-1828. doi: 10.1007/s13346-020-00840-2.
In this study, the development and the performance of a new targeted liquid crystalline nanodispersion (LCN) by the attachment of cell-penetrating peptides (CPP) onto their surfaces to improve skin delivery of lipoic acid (LA) were evaluated. For that, the synthesis and characterization of this new platform as well as its spatiotemporal analysis from in vitro and in vivo topical application were explored and extensively discussed in this paper. The TAT or D4 peptides were chosen as CPP due to specific target strategies by the charge grouping on the skin surface or target the overexpressed epidermal growth factor receptor (EGFR) of cell membrane of keratinocytes, respectively. Thus, the nanoparticle characterization results when taken together suggested that designed LCNs maintained their hexagonal phase structure, nanoscale particle size, and low polydispersity index even after drug, lipopolymers, and peptide additions, which are proved to be favorable for topical skin delivery. There were no statistical differences among the LCNs investigated, except for superficial charge of LCN conjugated with TAT which may have altered the LCN zeta potential due to cationic charge of TAT amino acid sequence compared with D4. The cumulative amounts of LA retained into the skin were determined to be even higher coming from the targeted LCNs. Moreover, the exogenous antioxidant application of the LA from the LCNs can prevent ROS damage, which was demonstrated by this study with the less myeloperoxidase (MPO) activity and decrease in cytokine levels (TNF-alpha and IL-1β) generated by the oxidative stress modulation. Together, the data presented highlights the potential of these targeted LCNs, and overall, opens new frontiers for preclinical trials.
在这项研究中,通过将细胞穿透肽(CPP)附着在其表面上,开发了一种新的靶向液晶纳米分散体(LCN),以改善脂酸(LA)的皮肤传递。为此,本文探索并广泛讨论了这种新平台的合成和表征及其从体外和体内局部应用的时空分析。选择 TAT 或 D4 肽作为 CPP,是因为它们在皮肤表面上具有特定的靶向策略,或者靶向细胞膜上过度表达的表皮生长因子受体(EGFR)的角蛋白细胞。因此,当综合考虑纳米粒子的特征结果时,表明设计的 LCN 保持了其六方相结构、纳米级粒径和低多分散指数,即使在药物、脂质体和肽添加后也是如此,这被证明有利于局部皮肤传递。除了与 TAT 缀合的 LCN 的表面电荷外,研究的 LCN 之间没有统计学差异,这可能由于 TAT 氨基酸序列的阳离子电荷而改变了 LCN 的 ζ 电位。从靶向 LCN 中保留在皮肤中的 LA 的累积量甚至更高。此外,LA 从 LCN 中的外源性抗氧化剂应用可以预防 ROS 损伤,这是本研究通过减少髓过氧化物酶(MPO)活性和降低氧化应激调节产生的细胞因子水平(TNF-α和 IL-1β)来证明的。总之,所呈现的数据突出了这些靶向 LCN 的潜力,并且总体上为临床前试验开辟了新的前沿。